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Abstract
Approximately 40,000 women will die from breast cancer in the United States in 2014.
About 90% of these deaths will be due to metastases, rather than the primary tumor and majority
of metastases are due to the recurrence and progression of non-metastatic disease. Current
adjuvant treatments, such as chemotherapy and radiation, have severe side effects and may result
in overtreatment and drug resistance.
Since greater than 90% of patients are diagnosed between stages I-III and have minimal
residual disease after treatment, there is an opportunity to treat patients with an autologous breast
cancer vaccine. Autologous vaccines under development have a multivalent antigen repertoire,
nontoxic side effects and most importantly, allow for personalized, patient specific treatment. A
vaccine may be able to eliminate remaining tumor cells following primary treatment, prevent a
recurrence and result in improved survival.
We developed an autologous breast cancer vaccine using two murine cell lines, 4T1 and
EMT6, to demonstrate the potential of vaccines for adjuvant treatment of breast cancer. We first
tested two commonly used methods of inactivating cells, irradiation and freeze/thaw cycling, to
see if either method was superior in establishing protective immunity. Next, we measured
surface expression of MHC I, MHC II, Fas, ICAM-1, B7-1 and B7-2 and secretion of the
immunosuppressive cytokines GM-CSF, IL-6, MCP-1, TGF-β, and VEGF by each cell line to
better understand differences in immunogenicity.
In the EMT6 model, vaccination with irradiated cells provided protection from live tumor
challenge in 80% of mice, while no protection was seen following vaccination with
freeze/thawed cells. Furthermore, a minimum threshold of 250,000 irradiated cells was needed to
elicit an anti-tumor response. In the 4T1 model, no protection was generated by irradiated or

freeze/thawed vaccines. After measurement of surface molecules, B7-1 was up-regulated
following irradiation in EMT6 cells, but not 4T1 cells. IFN-γ was used to up-regulate surface
markers on 4T1 cells. Additionally, EMT6 cells secreted higher levels of IL-6, MCP-1, TGF-β,
and VEGF, while 4T1 cells secreted higher levels of GM-CSF. Expression of B7-1 and GMCSF may potentially drive differences in immunogenicity.

Acknowledgements
I would like to thank my research advisor, Dr. David Zaharoff, for giving me the
opportunity to explore the world of research and for his continuous support and guidance
thereafter. This thesis wouldn’t have been possible without his assistance and encouragement.
I would also like to thank my family for their support during the undertaking of this
degree and for always believing in me.

Table of Contents
Chapter 1: Introduction to Breast Cancer .....................................................................................1
Diagnosis and Staging .............................................................................................................1
Subtypes ..................................................................................................................................3
Treatment ................................................................................................................................3
Recurrence ..............................................................................................................................5
Objective .................................................................................................................................7
Chapter 2: Autologous Whole Tumor Cell Vaccines for Breast Cancer .......................................8
Introduction .............................................................................................................................8
Advantages of Autologous Tumor Cell Vaccines ................................................................... 10
Disadvantages of Autologous Tumor Cell Vaccines ............................................................... 11
Clinical trials with Autologous Breast Cancer Vaccines ......................................................... 12
Autologous Tumor Cell Vaccines for Other Cancers .............................................................. 14
Preclinical Studies of Autologous Whole Tumor Cell Vaccines ............................................. 15
Chapter 3: Characterization of Immunogenicity in Two Breast Cancer Cell Lines ..................... 17
Introduction ........................................................................................................................... 17
Methods................................................................................................................................. 18
Results ................................................................................................................................... 22
Discussion ............................................................................................................................. 46
Chapter 4: Future Perspective .................................................................................................... 52
Introduction ........................................................................................................................... 52
Future Pre-Clinical Studies .................................................................................................... 53
Implementation in the Clinic .................................................................................................. 55

References ................................................................................................................................ 56
Appendix .................................................................................................................................. 63
Figures .........................................................................................................................................
Figure 1 ................................................................................................................................. 24
Figure 2 ................................................................................................................................. 26
Figure 3 ................................................................................................................................. 28
Figure 4 ................................................................................................................................. 29
Figure 5 ................................................................................................................................. 30
Figure 6 ................................................................................................................................. 32
Figure 7 ................................................................................................................................. 36
Figure 8 ................................................................................................................................. 39
Figure 9 ................................................................................................................................. 41
Figure 10 ............................................................................................................................... 43
Figure 11 ............................................................................................................................... 45

Chapter 1: Introduction to Breast Cancer
Diagnosis and Staging
About 295,240 women will be diagnosed with breast cancer in the United States in 2014.
Majority of these cases, about 232,670, will be invasive breast cancer, while the other 62,570
cases will be carcinoma in situ, or pre-cancer. In addition to being the most diagnosed cancer,
breast cancer is the second leading cause of cancer death in women. In 2014, about 40,000
women will die from breast cancer. Once a woman is diagnosed with breast cancer, the cancer is
given a stage based on extent of disease. The cancer stage is one of the critical factors in
determining prognosis and treatment. Staging of a cancer is evaluated on size of the primary
tumor (T), number of nearby lymph nodes involved (N), and presence of metastasis (M). This is
called the TNM system. The category T is divided into 4 subcategories: T1 is 2 cm or less in
diameter, T2 is between 2 cm and 5 cm, T3 is more than 5 cm, and T4 is a tumor of any size
growing into the chest wall or skin. The category N is also divided into 4 subcategories: N0 is
no presence of tumor cells in lymph nodes, N1 is cancer has spread to 1-3 underarm lymph nodes
and/or micrometastases in the internal mammary lymph nodes (N1mi), N2 is cancer has spread
to 4-9 underarm lymph nodes or has enlarged mammary lymph nodes, and N3 is cancer has
spread to 10 or more underarm lymph nodes with one area greater than 2 mm or cancer has
spread to 4 underarm lymph nodes with one area greater than 2 mm and cancer is found in
internal mammary lymph nodes. The category M is divided into two subgroups: the absence of
metastatic disease (M0) or the presence of metastatic disease (M1) 1.
Information from the T, N and M categories are combined and given a single stage
grouping. The stage ranges from Stage I (least advanced) to Stage IV (most advanced). A
patient may be assigned a Stage 0 if the cancer is non-invasive. Most commonly this is ductal
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carcinoma in situ (DCIS) and is considered pre-cancer. The TNM system is combined to the
stage group as follows:
Stage I: T1, N0, M0
T0 or T1, N1mi, M0
Stage II: T0 or T1, N1, M0
T2 or T3, N0, M0
T2, N1, M0
Stage III: T0 to T2, N2, M0
T3, N1 or N2, M0
T4, N0 to N2, M0
Stage IV: any T, any N, M1
In general, an increase in the T, N, and M categories correlate with more advanced stage,
but as soon as distant metastases are present the cancer is Stage IV1. Majority of patients are
diagnosed with cancer between Stage 0 and Stage II. Approximately 20.3%, 41.4%, 23.8% of
women are diagnosed with Stage 0, I, or II, respectively. Only 8.3% of women are diagnosed
with Stage III cancer and 3.9% of women are diagnosed with Stage IV cancer2. Considering that
early diagnosis of breast cancer is critical for survival, it is beneficial that most breast cancer
patients are diagnosed at an earlier stage. As the number of tumor cells spreading through nearby
lymph nodes and establishing in distant organs increases, the harder the cancer is to eliminate,
which is why early diagnosis of breast cancer is key. For example, the relative 5 year survival
rate for breast cancer patients is 100%, 93%, 72% and 22% for Stage I, II, III and IV,
respectively1. The low survival rate for stage IV disease is directly related to the establishment
of distant metastases and the inability to eradicate all of the tumor cells.
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Subtypes
In addition to staging of breast cancer, presence of the hormone receptors, estrogen
receptor (ER) and progesterone receptor (PR) and human epidermal growth factor receptor
(HER2/neu) is also considered when giving a prognosis and treatment. Breast cancers can be
divided into 4 subtypes: luminal A, luminal B, triple negative and HER2 type. The most
common subtype is luminal A, which has presence of one or both hormone receptors and is
HER2 negative. Luminal B contains one or both hormone receptors and is HER2 positive.
Triple-negative subtype lacks all three receptors, while the HER2 subtype only expresses the
HER2 and no hormone receptors3.
Luminal tumors look most like the cells (luminal cells) on the inner lining of mammary
ducts and are the most frequently diagnosed accounting for 40% (Luminal A) and 20% (Luminal
B) of all diagnoses. Of all of the subtypes, luminal A usually has the best prognosis. Compared
to luminal A, luminal B is associated with having larger tumors or positive lymph nodes. The
prevalence of TNBC and HER2 type ranges from 15-20% and 10-15% of all diagnosed breast
cancers, respectively. Both triple negative and HER2 type are often aggressive and associated
with recurrence and metastases. The receptor status of each tumor must be considered when
treating breast cancer patients because some treatments, like hormone or targeted therapy, will
only work on patients with tumors that express ER, PR or HER2 3.

Treatment
The primary treatment of breast cancer is surgery and is usually followed by adjuvant
therapy including chemotherapy, radiation, hormone therapy and/or targeted therapy. Surgery
options include either a partial mastectomy or a mastectomy. A partial mastectomy involves
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removal of the tumor and surrounding tissue, called a lumpectomy, or removal of up to a quarter
of the breast, called a quadrantectomy. After tissue removal, edges of the tumor are examined by
a pathologist for presence of tumor cells. If tumor cells are not found, the tissue has “negative
margins” and no further surgery may be needed. If tumor cells are found, the tissue has “positive
margins” and tumor cells may have been left behind. The surgeon may go back to remove more
tissue or perform a mastectomy. Mastectomy involves whole breast removal, and possibly
nearby tissues such as underarm lymph nodes and chest muscles behind the breast. A few lymph
nodes may be resected during primary surgery or a biopsy may be performed to check for
presence of cancer cells. Analysis of lymph nodes is important to determine the stage of breast
cancer and potential treatment following surgery1.
After surgery if no cancer is detectable, then patients are usually given adjuvant therapy
in an effort to prevent a recurrence. It is thought that early in tumor development tumor cells
leave the primary tumor and begin to spread throughout the body. Although these cells exist,
they are undetectable and may begin to replicate and establish a second tumor elsewhere in the
body. Adjuvant therapy is given in an effort to eliminate these lingering tumor cells following
surgery. Chemotherapy is a systemic therapy given to approximately 80% of patients to
eliminate tumor cells that have migrated from the tumor4. In advanced stage patients,
chemotherapy may be the main treatment modality. Chemotherapy works by attacking quickly
dividing tumor cells, but in addition attacks noncancerous quickly dividing cells such as those
from our bone marrow, hair follicles, and lining of our mouth. This results in side effects such as
hair loss, mouth sores, low blood cell counts along with toxic side effects like neuropathy, heart
damage and “chemo-brain”. Radiation therapy is a local treatment given at the tumor site. In
breast conserving surgery, radiation treatment is given to lower the chance that the cancer will
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come back in the breast or nearby lymph nodes. After a mastectomy, radiation treatment may be
given if the tumor was larger than 5 cm or if cancer cells were found in the lymph nodes1.
Hormonal therapy, such as Tamoxifen, may also be given as an adjuvant therapy to breast
cancer patients. Estrogen promotes the growth of cancers that is hormone-receptor positive and
hormonal therapy either lowering estrogen from acting on the cancer or lowering estrogen levels.
Side effects of tamoxifen include fatigue, hot flashes, mood swings and possibly more severe
side effects such as secondary cancers of the uterus and blood clots. However, this therapy is
only given for hormone receptor positive tumors. Similar to hormonal therapy, targeted therapy,
such as trastuzumab (Herceptin), relies on the presence of HER2 on the surface of tumor cells.
Elevated HER2 expression is associated with an aggressive growing and spreading tumor 1.
Trastuzumab attempts to slow down cancer growth by use of a monoclonal antibody targeting
HER2 to block the cell from receiving growth signals1. Compared to chemotherapy, side effects
aren’t as severe and include fever, chills, weakness, nausea and vomiting with a potential severe
side effect of heart failure.
Some patients may receive chemotherapy or hormonal therapy prior to surgery, which is
called neoadjuvant therapy. The goal of neoadjuvant therapy is to shrink the tumor and allow for
a less invasive surgery. If a patient receives neoadjuvant therapy, they may not receive any
adjuvant therapy.1

Recurrence
After treatment, if not all cancer cells are eliminated, the cancer may come back either
locally or distantly (metastases) and this is called a recurrence. A local recurrence may come
back as cancer in the breast or in the surrounding chest area. The treatment following a local
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recurrence is similar to treatment of the primary tumor. If the patient originally had a
lumpectomy, often the patient undergoes a mastectomy and receives some sort of adjuvant
therapy. If the patient originally had a mastectomy, the secondary tumor is removed and often
followed with radiation and/or other adjuvant therapies1.
Distant recurrences most often occur in the bones, lung, liver or brain. Treatment after a
diagnosis of metastases focuses more on the length and quality of life of the patient, rather than
removing the cancer using the same therapies used to treat the primary tumor. Although
metastatic cancer is treatable, it is not curable1.
The possibility of a recurrence depends on a few different factors including the number of
positive lymph nodes at the time of primary surgery and the breast cancer subtype. For stages I,
II, and III the recurrences rates after 5 years are 6.9%, 11.2% and 12.7%, respectively. After 10
years, the recurrence rates increase to about 20% 5. Additionally, a greater chance of recurrence
is associated with more aggressive tumors, such as TNBC. For example, 6 years after diagnosis
almost a third of TNBC patients have a recurrence compared to only 10% of all breast cancer
patients. TNBC patients divided into their cancer stage at diagnosis show a distinct increase in
recurrence corresponding with a higher cancer stage. The prevalence of recurrence 5 years after
diagnosis in TNBC patients is about 7%, 33%, and 60% for stages I, II and III, respectively6. As
evident by these statistics, an increase in recurrence is associated with extent of disease at time of
diagnosis and more aggressive breast cancer subtypes.
Since 90% of breast cancer deaths are due to metastases7 and only 3.9% of patients are
diagnosed with stage IV cancer1, majority of breast cancer deaths are due to the recurrence of
non-metastatic disease. A non-toxic specific therapy is needed to target lingering tumor cells
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following surgery in an effort to decrease breast cancer recurrence, and therefore increase
survival rate.

Objective
The overall objective of this project was to develop and characterize an autologous tumor
cell vaccine using a murine model that may be able to prevent recurrences and therefore result in
improved overall survival. An autologous tumor cell vaccine is a form of active specific
immunotherapy (ASI) that utilizes inactivated patient specific tumor cells to launch an antitumor immune response. Active stimulation of the immune system is one advantage of an
autologous vaccine over current passive targeted therapies. By using patient-specific tumor
cells, numerous known and unknown antigens may be targeted at once ensuring a personalized
and potentially polyclonal immune response with minimal toxicity.
In this study, we used two murine breast cancer cells lines, 4T1 and EMT6, to develop an
autologous vaccine. Both cell lines were used in order to compare their inherent immunogenic
qualities relating to the vaccine and in vitro characterization. The 4T1 cell line is known as a
non-immunogenic cancer representing human stage IV breast cancer, while the EMT6 cell line is
relatively immunogenic. For each cell line, we first pursued the most immunogenic way to
inactivate tumor cells. Two commonly used methods were used to inactivate cells, irradiation
and freeze/thaw, and given as prophylactic vaccines to see if there was any difference in
protection after a challenge with live tumor cells. An immunogenic profile was then created for
each cell line based on surface molecule expression and immunosuppressive cytokine secretion.
These are two characteristics that tumors use to evade the immune system, specifically T
lymphocytes. We hoped to determine a few key differences in the immunogenic profile between
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each cell line. Based on the differences, an immunogenic tumor may be engineered from a nonimmunogenic tumor by manipulating various immunogenic characteristics and therefore promote
an anti-tumor immune response.

Chapter 2: Autologous Whole Tumor Cell Vaccines for Breast Cancer
Introduction
Approximately 232,570 women will be diagnosed with invasive breast cancer and 40,000
women will die from breast cancer in the United States in 20141. However, 90% of breast cancer
deaths are due to metastases to the bone, brain, lung and liver, not the primary tumor 7.
Considering only 3.9% of breast cancer patients are diagnosed with metastatic Stage IV cancer,
majority of these metastases and deaths are due to the recurrence and progression of nonmetastatic disease2. For example, 7% of Stage I patients will experience tumor recurrence after 5
years, while 11% and 13% of patients with Stage II and Stage III, respectively will experience
tumor recurrence. After 10 years, the overall breast cancer recurrence rate is about 20% 5.
In an effort to combat tumor recurrence, majority of patients receive adjuvant therapy
such as chemotherapy and/or radiation. Chemotherapy is routinely offered to about 80% of
patients4 even though the benefits are limited especially in older patients. Following
chemotherapy treatment, patients younger than 50 years of age increase their 5 year survival rate
by 4.7% while only a 2.6% increase is seen in patients older than 508. Chemotherapy normally
includes a combination of drugs, such as anthracyclines or taxanes, and has toxic side effects
including hair loss, mouth sores, low blood cell counts, neuropathy and “chemo-brain”1.
Radiation is also used an as adjuvant to treat breast cancer patients. A meta-analysis showed only
a 5% decrease in 15-year breast cancer mortality risk 9. Overtreatment with chemotherapy and/or
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radiation can occur either by treating patients that do not need adjuvant therapy or administration
of more aggressive treatment than necessary. A recent estimate suggests that 1 to 3 deaths occur
due to overtreatment for every breast cancer death evaded 10. Although chemotherapy and
radiation increases survival rate for breast cancer patients, it comes with severe side effects,
overtreatment results in unnecessary deaths and 1 in 5 patients still have a recurrence after 10
years. These recurrences result after adjuvant therapy due to the inability to eliminate all hidden
tumor cells and may then acquire drug resistance 11, 12. Due to severe side effects, overtreatment,
and drug resistance with current adjuvant therapies there is a need for more effective
interventions to limit recurrence and progression.
In 2010, the FDA approved sipuleucel-T (Provenge), an active cellular immunotherapy
for the treatment of advanced prostate cancer. Since then, there has been a movement towards
research of active specific immunotherapies (ASI) for the treatment of cancer. ASI is the use of
tumor specific antigens to stimulate the adaptive immune system and launch an immune
response against a tumor. In theory, after exposure to tumor antigens, tumor specific
lymphocytes would be able eradicate all tumor cells and establish an immune memory. Breast
cancer would be an ideal disease for the use of ASI due to the delay of recurrence after treatment
and the thousands of patients eligible for this therapy. The time period before a recurrence would
allow the immune system time to be stimulated by ASI, activate T lymphocytes to eradicate
residual disease, and memory T lymphocytes to maintain immune memory of breast cancer.
Since greater than 90% of patients are diagnosed between stages I-III and have minimal residual
disease after treatment, ASI has the potential to benefit thousands of breast cancer patients from
a recurrence, and therefore result in improved overall survival.
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ASI can be accomplished using different vaccine formulations classified by the form of
antigen and how they are administered. Antigens can be presented to the immune system as
whole tumor cells 13, tumor specific peptides or tumor associated peptides 14, 15, carbohydrates 16
or cell lysates 17. In addition, antigens can be delivered as inactivated whole cells 18, 19, pulsed
with dendritic cells 20, 21, or delivered with cytokines or other immunomodulators 13, 21, 22.

Advantages of Autologous Tumor Cell Vaccines
Autologous tumor cells have a number of advantages when used as ASI, including having
a multivalent antigen repertoire and patient specificity. An ideal cancer antigen has
immunogenicity, oncogenicity, and specificity. Out of 75 cancer antigens analyzed by Cheever
et al., none of the antigens satisfied all criteria for an ideal cancer antigen 23. However, by using
many antigens, both known and unknown, the ideal cancer antigen criteria may be satisfied
among all of the available antigens to allow a higher immune system response. Additionally, by
using autologous cells all potential antigens are being shown to the immune system. More than
one potential antigen can be targeted at once, eliminating the problem of antigen loss and
potentially activating a polyclonal immune response 13, 22. Importantly, all of the potential
antigens are directly from the patient’s own tumor, therefore ensuring that patients are exposed
to the antigens that their own tumor expresses 13. There are an estimated 105 mutant genes in
breast cancer and a personalized approach can be taken to ensure these mutations are recognized
by a patient’s immune system 24. These inactivated whole tumor cells could enable a patient’s
own immune system to specifically destroy remaining cancer cells left after surgery and prevent
the development of recurrence 25.
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Furthermore, autologous whole tumor cells may be beneficial to even the aggressive
triple negative breast cancer (TNBC). TNBC is a lethal subtype of breast cancer that has a
greater risk of recurrence and shortened survival compared to hormone positive subtypes and has
a 5 year survival of ~90%, ~78%, and ~35%, for stage I, stage II, and stage III-IV, respectively
26

. However, poor survival of TNBC can be partly explained by limited treatment options since

hormonal and HER2 treatments do not benefit TNBC patients. By inactivating whole TNBC
tumor cells, expression of current unknown antigens may be presented to the immune system and
elicit a patient-specific adaptive immune response.

Disadvantages of Autologous Tumor Cell Vaccines
Preclinical and clinical studies have presented some challenges with development of
autologous tumor cell vaccines. First, harvesting enough tumor cells can be inefficient and time
consuming 13. In a study by Avigan in 2004, only 16 of 32 vaccines were successfully generated.
Vaccines were composed of fusions of dendritic cells and tumor cells which were then irradiated.
Tumor cells did not expand ex vivo and tumor tissue smaller than 1cm did not provide adequate
cell yields 27. However, Elliott and Head mention obtaining 10,000,000 cells from a 1cm3 tumor
28

. The differences in tumor cell yield may be due to a lack of standardization of autologous

tumor vaccine preparations which does not allow comparable results 29. Tumors can be
dissociated and then inactivated in a variety of ways. Tumors can be dissociated enzymatically
with collagenase and DNAse 28, mechanically, or both 30. Once in a single-cell suspension,
tumor cells can be inactivated by irradiation 31, 32, freeze-thaw 30 or mitomycin-C 28.
Additionally, while some protocols mention separating tumor cells from other cells in the
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suspension, others do not 28, 31-33. It is uncertain which method(s) induces the most immunogenic
vaccine.
Furthermore, tumor cells are mainly composed of normal antigens 22. The tumor antigens
present are only mildly immunogenic and self-like, therefore the immune response is not strong.
Also, tumor cells do not express enough costimulatory proteins to produce a significant response
25

. Delivery systems and adjuvants are under exploration to increase immunogenicity.

Clinical trials with Autologous Breast Cancer Vaccines
To our knowledge, there have only been four clinical trials exploring autologous breast
cancer tumor cell vaccines, two of which are ongoing. Majority of the clinical trials involving
autologous vaccines for any cancer have only been phase I/II trials with small numbers of
advanced stage patients. These patients have larger, metastatic tumors that secrete
immunosuppressive factors and a poor immune status 34. Since tumor cells alone have shown to
be poorly immunogenic, there has been no trial testing of autologous cells alone. Instead, several
trials using transfected autologous tumor cells have been explored. Autologous cells have often
been genetically modified to express cytokines, chemokines or costimulatory molecules in order
to make the vaccine more immunogenic 13. GM-CSF has shown to be an effective costimulatory
cytokine due to its ability to activate a tumor targeted T cell response by recruitment of dendritic
cells. The dendritic cells are then able to uptake, process and present the antigen 13. Although
GM-CSF has been used as an immune adjuvant, if given at high doses over a sustained period of
time it can cause immunosuppression by recruitment of MDSCs. A minimal dose to achieve
desire immunogenic effects must be greater than 36 μg/day, but lower than 100-500 μg/day 35.
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There are currently two active clinical trials registered in the NIH Clinical Trial database
investigating autologous breast cancer cells that have been engineered to express GM-CSF. Both
are phase I/II trials sponsored and collaborated by Dana-Farber Cancer Institute and Brigham
and Women’s Hospital. One trial is strictly for metastatic breast cancer patients36, while the other
is for breast cancer stages II-III37. The study completion date for metastatic patients is January
2015 and the study completion date for stages II-III is April 2015 with a primary completion date
of April 2014.
A study conducted by Ahlert et al.33 explores a vaccine comprised of autologous breast
tumor cells infected with Newcastle disease virus (NDV). Primary breast cancer and metastatic
breast cancer patients were treated with an autologous tumor cell vaccine infected with non-lytic
NDV. Primary breast cancer patients started immunotherapy following surgery and were given at
least two vaccinations. If applicable, chemotherapy and radiation was administered 28-35 days
after the start of immunotherapy. Metastatic breast cancer patients followed this same protocol
with the addition of IL-2/IFNα-2a and anti-suppressive drugs, such as cyclophosphamide and
epirubicin. Vaccine quality was divided into high and low quality. The high quality group had a
median count of 1.5x106 viable tumor cells for each vaccine and median viability greater than
33%. The low quality group did not meet one of these qualifications. After 4 years, a significant
difference was seen in patients with primary breast cancer: 96% of patients with a high vaccine
quality were alive compared to 68% with a lower vaccine quality. An increase in survival was
also observed in metastatic breast cancer patients with a high quality vaccine compared to a low
quality vaccine, although the difference was not significant (P= 0.18) due to low patient
numbers. 33. It is not clear whether any follow-up studies were performed despite promising
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results. This study also represents the importance of developing and standardizing vaccine
preparations.
In a study using autologous cells with other antigens, Elliott and Head 28 used a
vaccination with autologous breast tumor cells, allogeneic breast tumor cells, and 3 antigens
combined with IL-2 and GM-CSF given to patients with depressed lymphocyte immunity. All
patients underwent surgery and were finished with chemotherapy and/or radiation treatment prior
to immunotherapy. Immunocompetency was determined at least 10 weeks after completion of
adjuvant therapy and evaluated host reactivity to tumor antigens. Patients with depressed
lymphocyte immunity were given a total of 6 vaccines on weeks 1, 2, 3, 7, 11 and 15. They
concluded that disease specific survival of vaccinated patients with depressed immunity (89%)
was significantly different than patients with depressed immunity that were unvaccinated (59%)
28

.

Autologous Tumor Cell Vaccines for Other Cancers
Although there have not been many clinical trials reporting autologous vaccines for
treatment of breast cancer, autologous whole tumor cell vaccines are being explored in numerous
other cancers. Phase I clinical trials of autologous tumor cells administered with
immunomodulators such as GM-CSF and BCG have been reported in colon cancer32,
hepatocellular carcinoma38, melanoma39, among other cancers. As a whole, these trials
demonstrated the safety of this vaccine with a potential for clinical benefit
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. Several of the

intriguing results are highlighted to demonstrate the potential of autologous vaccines.
An autologous tumor cell vaccine for metastatic melanoma suggests a few notable
conclusions. Patients were vaccinated with irradiated tumor cells weekly for 3 weeks and then
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monthly for 5 months. A better overall survival was seen in patients with minimal disease,
patients treated with GM-CSF or IFN-γ as adjuvant, or patients receiving an average of <7
million cells for the first three vaccinations. The 5 year overall survival for patients with minimal
disease was 47% compared to 13% for patients with metastatic disease. The 5 year event-free
survival for patients treated with adjuvant cytokines was 26% compared to 0% for patients
without adjuvant treatment. In addition, patients with <7 million cells per vaccination had a 5
year event-free survival of 35% compared to 24% of patients with >7 million cells per
vaccination. The vaccine produced minimal toxicity and was associated with long-term survival
39

.
A study done by Peng et al. showed that an autologous tumor vaccine lowered the post-

surgical recurrence rate of hepatocellular carcinoma. Patients treated with a vaccine had a 3 year
recurrence rate of 54%, while the control group had a 72.1% recurrence rate 38. All of these
vaccines were safe and well-tolerated.
One Phase III trial using autologous whole cells was reported in colon cancer. This trial
consisted of autologous colon cancer cells with BCG (OncoVax) and has shown a statistically
significant improvement in recurrence-free survival and overall survival, specifically in Stage II
patients 32. Most importantly, the results showed a 61% decrease in recurrence rate with ASI
compared to no treatment following curative surgery 41.

Preclinical Studies of Autologous Whole Tumor Cell Vaccines
Similar to clinical trials, not many pre-clinical studies have explored autologous breast
cancer vaccines. To our knowledge, there has not been a single lab animal study using
autologous vaccines in the therapeutic setting. However in the prophylactic setting, inactivated
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tumor cells can elicit a protective immune response depending on the aggressiveness of the
murine cancer cells. The immunogenic TS/A mammary cancer cell line has been shown to elicit
protective immunity 42, while less immunogenic EMT6 mammary carcinoma cell line 43 and nonimmunogenic mammary 4T1 cell line do not 42. However, van Pel and Boon demonstrated in
1982 that protective immunity could be induced in mice with non-immunogenic tumors. The key
point was that cells used to immunize the mice must have been exposed to a DNA damaging
agent 44. In addition, the lack of tumor immunogenicity was not a lack of tumor antigens, but
rather an inability of the immune system to be stimulated due to immunosuppression 44. In an
effort to overcome immunosuppression, a variety of immune system adjuvants have been
administered with cancer cells. By adding immune system adjuvants, most commonly GM-CSF
and/or IL-2, a higher protective immunity is seen than by autologous cells alone 45. Additionally,
immunosuppression specifically occurs around a tumor microenvironment, but there is a
“window of opportunity” 7-10 days after surgical removal of the tumor with decreased immune
suppression 46. The knowledge gained from van Pel and Boon’s study has been applied to nearly
every murine tumor system 44. By decreasing immunosuppression through addition of adjuvants
or tumor resection, we can elicit a high protective immunity. We know that autologous cell
vaccines work in some murine tumors and this gives hope for successful human vaccines.
Although autologous whole tumor cell vaccines have shown substantial pre-clinical
success, it is not evident why some murine cell lines elicit protective immunity while others will
not. We want to continue studying in the murine system to improve our understanding of what is
the right context for a vaccine to be most effective. Using two murine cell lines, we may
compare the inherent immunogenic qualities and hope to determine some key factors that
influence immunogenicity. By understanding factors that mediate the anti-tumor immune
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response in the murine system, we may be able to apply our knowledge to the clinical setting and
improve clinical success.

Chapter 3: Characterization of Immunogenicity in Two Breast Cancer Cell Lines
Introduction
Current adjuvant therapies for breast cancer are effective at prolonging survival, but still
many patients relapse and toxicity is significant. Therefore, we sought to develop an autologous
whole breast cancer cell vaccine due to the favorable safety record and patient-specific approach
of breast cancer treatment. Autologous cells may specifically engage the immune system to
eliminate lingering tumor cells following primary treatment. Furthermore, because lumpectomy
or mastectomy is indicated for the vast majority of breast cancer patients, resected tumors offer a
readily available, patient-specific source of tumor antigen. However, little clinical success has
been observed due to the “self-like” quality of tumor cells, immunosuppression of tumor bearing
patients and vaccinating in patients with extensive disease. In this study, we used two murine
breast cancer cell lines, 4T1 and EMT6, as the basis for the development of an autologous
vaccine.
First, we determined the most immunogenic way to inactivate tumor cells using two
common cell inactivation methods, irradiation and freeze/thaw cycling. After noticing
differences in immunogenicity between the two cell lines, surface marker expression and
immunosuppressive cytokine secretion was measured in hopes of identifying some key
differences between each cell line. To further study the immunogenicity of these cell lines, a
hybrid vaccine consisting of both cell lines was given to determine whether presence of 4T1 cells
altered protection immunity against EMT6 cells. By identifying differences between each cell
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line, manipulations may be made to better understand what significantly influences the
immunogenicity of each cell line. Additionally, using the inherent immunogenic cell line, mice
were vaccinated with varying cell doses to determine a minimum threshold of cells that will
induce an anti-tumor immune response. Ultimately, our goal is to create immunogenic cells that
will elicit an anti-tumor immune response against an inherently non-immunogenic cell line. The
following data represent a significant first step in the development of a more effective autologous
tumor cell vaccine for use as an adjuvant therapy for breast cancer.

Methods
Mice and Tumor Cell Culture
Female six to eight week old BALB/c mice were obtained from the Jackson Laboratory
(Bar Harbor, ME). Mice were housed and maintained under pathogen-free conditions in
microisolator cages. Animal care was under compliance with the recommendations of The
Guide for Care and Use of Laboratory Animals (National Research Council). 4T1 and EMT6
murine mammary carcinoma cells were obtained from American Type Culture Collection
(Manassas, VA). The 4T1 cell line was maintained in DMEM supplemented with 10% fetal
bovine serum, 100 units/mL penicillin and streptomycin, and 2mM L-glutamine. The EMT6 cell
line was maintained in RPMI 1640 supplemented with 15% fetal bovine serum, 100 units/mL
penicillin streptomycin, and 2mM L-glutamine. Cultures were maintained in a 37°C atmosphere
with 5% CO2.

Proliferation Assay
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4T1 and EMT6 cells were suspended in medium and irradiated at varying doses. Cells
were either not irradiated (0 Gy) or irradiated at 20, 40, 60, 80, or 100 Gy using a cesium
irradiator. Cells were plated in triplicate in a 96 well plate for each irradiation dose with 200 μl
of medium. After 24, 48, 72 and 96 hours of incubation, 20 μl of CellTiter 96 Aqueous One
Solution Reagent (Promega, Madison, WI) was added to each well and incubated for an
additional hour. Absorbance was read at 490 nm using a Biotek Synergy 2 plate reader. This
reagent is a colorimetric way to determine the number of viable cells in proliferation assays
through conversion of MTS to formazan by metabolically active cells.

Tumor Vaccines & Challenge
Prior to all vaccines and challenges, mice were anesthetized with ketamine (75
mg/kg)/xylazine (15 mg/kg) injected intraperitoneally. Inactivated cells comprising the vaccine
were injected subcutaneously on the right hind flank, while the live tumor cell challenge was
administered subcutaneously on the left hind flank. Tumors were measured with calipers in two
perpendicular diameters every 3 to 4 days. Tumor volume was calculated according to the
equation V(mm3)= ½( long width * short width2). Mice were euthanized by cervical dislocation
when volume reached 2000 mm3.

Irradiated versus Freeze/Thawed Vaccines
Cells were γ-irradiated at 100 Gy while suspended in medium at a concentration of 7,000
cells/μl. After irradiation, cells were centrifuged at 2000rpm for 5 minutes and resuspended in
DPBS. For cell lysis, cells were subjected to 5 freeze/thaw cycles while suspended in DPBS
using a 37°C water bath and liquid nitrogen. Mice were injected with 1x106 irradiated or

19

freeze/thawed, 4T1 or EMT6 cells on days -20 and -10 prior to challenge. On day 0, mice were
challenged subcutaneously with 5x104 viable 4T1 cells or 5x105 viable EMT6 cells.

Hybrid Vaccine
4T1 and EMT6 cells were taken from in vitro culture, trypsinized, counted and
resuspended in medium at a concentration of 7,000 cells/μl. Cells were irradiated at 100 Gy
using a cesium irradiator and centrifuged at 2000rpm for 5 minutes, then resuspended in DPBS.
Each cell line was then combined in one tube and mixed to ensure uniform suspension. Mice
were injected with 1x106 4T1 cells and 5x105 EMT6 cells on days -20 and -10. On day 0, mice
were challenged with 5x105 EMT6 cells.

Irradiated Cell Dose Vaccines
EMT6 cells were taken from in vitro culture, trypsinized, counted and resuspended in
medium at a concentration of 7,000 cells/μl. Cells were irradiated at 100 Gy and centrifuged at
2000rpm for 5 minutes, then resuspended in DPBS. Mice were injected with 5x105, 2.5x105,
1.25x105, 6.25x104, or 3.12x104 irradiated EMT6 cells on days -20 and -10. On day 0, mice were
challenged with 5x105 EMT6 cells.

Detection of Secreted Cytokines
For detection of VEGF and latent TGF-, 1x106 tumor cells and irradiated tumor cells
were plated in a 6 well plate. Supernatants were taken at 24, 48, 72 and 96 hours after plating and
stored at -20°C (VEGF) or -80°C (TGF-) until ready for use. The VEGF ELISA kit (R&D
systems, Minneapolis, MN) was used with a 1:2 dilution for 4T1 samples and 1:12 dilution for
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EMT6 samples. The latent TGF- ELISA kit (BioLegend, San Diego, CA) was used without
dilutions. Each ELISA was performed following manufacturer’s protocol. For detection of GMCSF, IL-6, IL-10, and MCP-1, supernatants were taken as described above and measured using a
cytometric bead array kit (BD Biosciences, San Diego, CA) according to manufacturer’s
instructions and analyzed using FCAP Array v3 (BD Biosciences, San Jose, CA).

Antibodies and Flow Cytometry
Cells were suspended at a concentration of 500,000 cells /100 μl PBS per polypropylene
tube and stained with 1μg of the appropriate antibody for an hour at room temperature. When a
secondary antibody conjugated to a fluorophore was needed, samples were centrifuged and
supernatant discarded before resuspension and incubation with the secondary antibody for an
additional hour. Antibodies used were FITC-conjugated H-2Kb, PE-conjugated I-Ad/I-Ed, PECy7-conjugated CD95, FITC-conjugated CD54, APC-conjugated CD80, and PE-conjugated
CD86 (BD Pharmingen, San Diego, CA), ER, PR, ErbB2, PE-conjugated IgG1, and FITCconjugated IgG2a (Abcam, Cambridge, MA). Samples were analyzed and median fluorescent
intensity (MFI) was calculated using FlowJo software (BD Biosciences, San Jose, CA).

In Vitro Doubling Time
500,000 4T1 or EMT6 cells were plated in T25 flasks with 5 ml of medium and
incubated for 8, 12, 16, 20, or 24 hours. At each time point, three flasks were removed from
incubation. Cells were trypsinized, resuspended in 1 ml of medium, diluted in trypan blue and
counted. Doubling time was then calculated using an online cell doubling time calculator 47.
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Statistical Analysis
GraphPad Prism 6 was used for statistical analysis. For survival data, a log rank test was
used to compare survival of vaccinated mice to unvaccinated mice. For doubling time, a two
way ANOVA was used with a Bonferroni posttest. Means of each time point was compared for
each cell line. For cytokine secretion, a two way ANOVA was used with a Tukey posttest.
Groups compared were as followed: 4T1 vs. 4T1 irradiated, 4T1 vs. EMT6, 4T1 irradiated vs.
EMT6 irradiated, and EMT6 vs. EMT6 irradiated. In figures, asterisks were used to denote the
following significance levels: *p0.05; **p0.01; ***p0.001; ****p0.0001.

Results
Dose of Irradiation has no Effect on Proliferation of Tumor Cells
Before vaccinating mice with irradiated cells, an appropriate dose of irradiation needed to
be determined to adequately inactivate the cells in a timely manner. In 4T1 cells, no difference
was found between cells not irradiated and cells irradiated with any dose up to 48 hours after
seeding (Figure 1). Between 24 and 48 hours there was a slight increase in proliferation by all
doses of irradiation (0-100), but after 48 hours cells that received any dose of irradiation showed
no further increase in proliferation. Cells that received no irradiation showed a significant
increase in proliferation after 48 hours. After 72 and 96 hours, there was a significant difference
in proliferation of cells that received no irradiation and cells that received any dose of irradiation.
Throughout all time periods of proliferation measurement, no difference was seen between any
of the doses of irradiation.
For EMT6 cells, all cells (not irradiated and irradiated) showed a slight increase in
proliferation until 48 hours after incubation, but the cells that weren’t irradiated showed a
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slightly significant increase in proliferation compared to cells that were irradiated (Figure 1).
After 48 hours, cells that were irradiated no longer showed an increase in proliferation. However,
cells that received no irradiation continued to show an increase in proliferation that was
statistically significant from cells that received irradiation. Again, throughout all time periods of
proliferation measurement, no difference was seen between any of the doses of irradiation. For
each dose of irradiation, cells continued to slowly proliferate 48 hours after incubation and then
showed no further increase. Based on the proliferation of both 4T1 and EMT6 irradiated cells,
we concluded that dose of irradiation has no effect on the proliferation of cells.
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Figure 1: No difference in proliferation with varying irradiation doses. Both 4T1 and EMT6
cells were not irradiated (0 Gy) or irradiated with 20, 40, 60, 80 or 100 Gy and plated in a 96
well plate with 200μl of medium. At 24, 48, 72 or 96 hours after seeding, 20 μl of CellTiter 96
Aqueous One Solution Reagent was added to each well, incubated for an hour and read using a
plate reader at 490 nm to determine cell viability. Statistical analysis was performed in
GraphPad using a two way ANOVA with Tukey posttest. Error bars represent SEM. Asterisks
were used to denote the following significance levels: **p0.01; ***p0.001; ****p0.0001.

Dose of Irradiation has no Effect on Cytokine Secretion
Since dose of irradiation showed no effect on proliferation of cells, dose of irradiation
might have an effect on immunosuppressive cytokine secretion and therefore our vaccine. As
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shown in Figure 2, there is a general increase in GM-CSF and IL-6 secretion by 4T1 cells for
both not irradiated and irradiated cells as time increases. For both GM-CSF and IL-6, there is no
significant difference between irradiated and not irradiated cytokine secretion until 96 hours after
seeding. After 96 hours, there is a small significant difference in GM-CSF secretion between no
irradiation and 20, 40 or 80 Gy. There is a higher significant difference between 0 Gy and 60 or
80 Gy. No significant difference is seen in GM-CSF secretion between any of the irradiation
doses.
For IL-6, there is a general increasing trend in cytokine secretion as time after incubation
increases however this increase is not as drastic as the increase GM-CSF. A statistically
significant difference in IL-6 secretion between irradiated and not irradiated cells is not seen
until 96 hours after seeding. There is a small statistically significant difference between 0 Gy
and 60 or 80 Gy and a slightly higher statistically significant difference between 0 Gy and 100
Gy. Again, no difference is seen in IL-6 secretion between any of the irradiation doses. Since
there was no significant difference between 20-100 Gy of irradiation, we performed a literature
search to help decide an irradiation dose for a cell based vaccine. We chose 100 Gy based on the
information found in our literature search48,49.
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Figure 2: Cytokine secretion after varying doses of irradiation. 4T1 cells were not irradiated (0
Gy) or irradiated with 20, 40, 60, 80 or 100 Gy and plated in a 6 well plate with 5 ml of medium.
At 24, 48, 72 and 96 hours after plating, samples were taken from the 6 well plate and store at 80°C. Once all samples were collected, cytokine levels (mean  SEM) were measured with
CBA. Statistical analysis was performed in GraphPad using a two way ANOVA with Tukey
posttest. Asterisks were used to denote the following significance levels: *p0.05; **p0.01.

Irradiated Cells Provide Protection in Immunogenic Cell Line
To determine whether irradiated or freeze/thawed cells result in better protection when
given as a prophylactic vaccine, 1x106 irradiated or freeze/thawed cells were administered to
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healthy Balb/c mice 10 and 20 days before viable tumor cell challenge. Vaccinations began with
a tumor cell dose of 1,000,000 cells, which we thought was a reasonable amount of cells that we
may be able to extract from a tumor and later be able to vaccinate in the therapeutic setting.
Vaccinations were performed for both the 4T1 and EMT6 cell lines. As shown in Figure 3, no
protection was observed after vaccinations with either irradiated or freeze/thawed cells in the
4T1 cell line. After each vaccination with irradiated 4T1 cells, some mice developed small
tumors which regressed after a few days (data not shown). There was not a significant difference
in survival of vaccinated mice and control mice, which received no vaccinations. The median
survival was 35, 40 and 43 days for mice vaccinated with irradiated 4T1 cells, vaccinated with
freeze/thawed 4T1 cells and control mice, respectively.
However, 80% of mice (4/5) vaccinated with irradiated EMT6 cells survived over 150
days following viable EMT6 tumor cell challenge. One mouse developed a tumor after a long
delay between challenge with EMT6 cells and tumor growth. The tumor first appeared 42 days
after challenge with EMT6 cells (Figure 4). Like the 4T1 cell line, there was no protection
observed with freeze/thawed cells in the EMT6 cell line. The median survival for both mice
vaccinated with freeze/thawed EMT6 cells and control mice was 35 days. These data confirm
previous studies that irradiated cells provide better immune protection than freeze/thawed cells
when administered as a vaccine 50, 51.
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Figure 3: Irradiated EMT6 cells provide protection as a prophylactic vaccine. 1x106 4T1 and
EMT6 cells were irradiated with 100 Gy or were subject to five freeze/thaw cycles with liquid
nitrogen and a 37C water bath. Vaccines were given on day 10 and 20 prior to vaccine
challenge. On day 0, mice were challenged with 5x104 4T1 or 5x105 EMT6 viable tumor cells
and tracked for survival. Control mice were only challenged on day 0. Statistical analysis was
performed in GraphPad using the Log Rank test. Asterisks were used to denote the following
significance level: ***p0.001.
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Figure 4: Irradiated EMT6 cells provide protection as a prophylactic vaccine. 1x106 4T1 and
EMT6 cells were irradiated with 100 Gy or were subject to five freeze/thaw cycles with liquid
nitrogen and a 37C water bath. Vaccines were given on day 10 and 20 prior to vaccine
challenge. On day 0, mice were challenged with 5x104 4T1 or 5x105 EMT6 viable tumor cells
and tracked for survival. Control mice were only challenged on day 0. Tumor volumes were
measured every 3 to 4 days in two perpendicular directions using calipers. Statistical analysis
was performed in GraphPad using the Log Rank test.

EMT6 Cells Have a Faster Doubling Time than 4T1
In order to eliminate the possibility that 4T1 tumors grew out due to a faster growth rate,
doubling time for each cell line was calculated. Both cell lines showed no increase in the
number of cells prior to 12 hours after seeding. The 4T1 cell line actually had a slight decrease
in cell number before starting to increase after 16 hours. EMT6 cells showed a shorter lag phase
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and started to slowly increase after 12 hours of incubation. As shown in Figure 5, as early as 16
hours after seeding, there are significantly more EMT6 cells than 4T1 cells. The calculated
doubling time of EMT6 cells is 9.0 hours, while 4T1 cells have a 10.5 hour doubling time.
Therefore, EMT6 cells grow slightly faster in vitro than 4T1 cells do. This eliminates the
possibility that 4T1 escape protective immunity due to a faster growth rate.

Figure 5: In vitro doubling time of 4T1 and EMT6 cells. 500,000 cells were plated in T25 flasks
and cultured for various amounts of time. At 8, 12, 16, 20, 24 and 28 hours after seeding, flasks
were removed from incubation, trypsinized, centrifuged and resuspended for cell counting.
Flasks were counted in triplicate at each time point and number of cells reported is mean ± SEM.
Statistics were calculated in GraphPad using a two way ANOVA with Bonferroni posttest.
Asterisks were used to denote the following significance levels: *p0.05; **p0.01; ***p0.001;
****p0.0001.

Both 4T1 and EMT6 cells are classified as Triple Negative Breast Cancer
Since the subtype of breast cancer affects the aggressiveness and recurrence frequency of
the disease, the molecular subtype of each cell line was classified. Cells were stained with ER,
PR, and HER2 antibodies and analyzed using flow cytometry. Both 4T1 and EMT6 cells
showed no surface expression of either hormone receptors or HER2 meaning they fall into the
aggressive TNBC subtype (Figure 6). Since both cell lines are categorized as TNBC, the
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difference in immunogenicity between each cell line must not be related to the hormone
receptors or HER2 expression. Additionally, this means that we are working with two murine
cell lines that are associated with poor prognosis and have a tendency to recur, but that vaccines
may establish immune protection against even aggressive tumors that do not express any
receptors targeted by current therapies as evident by vaccination with irradiated EMT6 cells.
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Figure 6: Both 4T1 (red) and EMT6 (blue) cells lines have triple negative receptor status. Cells
were taken from culture and suspended in polypropylene tubes at a concentration of 500,000
cells/ 100μl PBS. Cells were stained with anti-ER, anti-PR, or anti-ErbB2 for an hour at room
temperature. Following incubation, tubes were centrifuged, supernatant discarded and
resuspended in PBS. Cells were then stained with PE anti-IgG1 or FITC anti-IgG2a for an hour
at room temperature. Tubes were again centrifuged and supernatant discarded a second time.
Cells were resuspended in PBS and acquired on a BD FACSCanto II flow cytometer. Data was
analyzed using FlowJo_V10. Gray shaded areas represent cells stained with only the secondary
antibody. Numbers represent the difference in median fluorescent intensity between the control
and stained cells (ΔMFI).
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Surface Marker Expression of 4T1 and EMT6 Cells
Surface molecule expression of each cell line was analyzed after a distinct difference was
observed between vaccinating with irradiated 4T1 or EMT6 cells. The presence or absence of
certain surface markers may influence activation and responses of effector T cells. Each surface
marker tested and their function is summarized in Table 1. Surface marker expression on 4T1
and EMT6 cells was measured along with irradiated forms of each cell to understand what was
presented to the immune system during both the vaccination and challenge. Irradiated cells were
found to naturally fluoresce slightly higher than normal cells and this phenomenon was taken
into account when considering up-regulation of surface markers following irradiation. One way
tumors may evade the immune system is by down regulating MHC I expression on the tumor
surface so that cytotoxic T lymphocytes (CTLs) cannot recognize the tumor cells52. Both 4T1
and EMT6 cells show similar expression of MHC I (Figure 7). After irradiation, both 4T1 and
EMT6 cells show a two-fold increase in ΔMFI MHC I expression. This suggests that both cell
lines should be able to activate CD8+ T cells. Additionally, CTLs should be able to recognize
4T1 cells as efficiently as EMT6 cells and that the cell lines are equally able to present antigen as
an irradiated vaccine.
MHC II is needed for the activation of helper T cells, which in some cases are necessary
for the differentiation of CTLs 52. MHC II is expressed by both 4T1 and EMT6 cells, and show a
distinct up-regulation of MHC II expression 24 hours following irradiation. A slightly higher upregulation is seen in 4T1 cells (four-fold increase), compared to EMT6 cells (three-fold
increase). Based on this information, both cell lines should be able to activate helper T cells.
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Along with MHC I and II, costimulatory molecules like B7-1 and B7-2 are needed to
initiate a strong effector T cell response 52. Slight B7-1 expression is seen in 4T1 cells with a
small up-regulation following irradiation. EMT6 cells express almost 5 times as much B7-1 as
4T1 cells, although the ΔMFI between the negative control and stained EMT6 cells is only 21.6
(Figure 7). However, irradiated EMT6 cells have an 11-fold increase in B7-1 expression
compared to before irradiation (Figure 7). EMT6 cells also express significantly more B7-1
following irradiation than 4T1 cells. As for B7-2, 4T1 and EMT6 cells have similar expression
and show some increase in expression following irradiation. This suggests that EMT6 cells may
be able to induce a strong effector T cell response due to B7-1 expression during vaccination,
while 4T1 cells are not as capable.
Another costimulatory molecule for the activation of T lymphocytes is ICAM-1, which is
specifically important for the costimulation of CD8+ T cells53. Before irradiation, both 4T1 and
EMT6 cells show little ICAM-1 expression with a ΔMFI of 8.4 and 12.1, respectively (Figure 7).
However following irradiation, 4T1 cells have a 5-fold increase in ΔMFI. The ΔMFI stays the
same before and after irradiation of EMT6 cells. This suggests that little costimulation signal
may be provided by ICAM-1 in the EMT6 cell line. In the 4T1 cell line, normal cells may
provide some costimulation while irradiated 4T1 cells provide slightly more costimulation.
After CD8+ T cells are activated, a granule-independent mechanism may be used by
CTLs to kill target cells. After CTLs are activated, they express Fas ligand (FasL) which may
then bind to a cell expressing Fas and induce apoptosis of the target cell 52. We found that both
4T1 and EMT6 cells show a distinct expression of Fas (Figure 7). EMT6 cells show a much
higher fluorescence intensity of Fas than 4T1 cells (8.8-fold increase). EMT6 cells show no
histogram overlap between the stained cells and control, while a distinct overlap is seen between
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4T1 stained cells and control. We can conclude that CTLs should be able to induce apoptosis of
tumor cells based on Fas expression, but may be able to better eliminate EMT6 tumor cells
through a granule-independent mechanism than 4T1 cells due to the distinctly higher Fas
expression. However, this is dependent on the presence of CTLs.

Table 1. Summary of Surface Molecules and Functions that may Influence Immunogenicity of
Tumor Cells.
Surface Molecule
MHC I
MHC II
B7-1
B7-2
ICAM-1
Fas

Function
Peptide presentation to CD8+ T cells
Signal 1 for T cell activation
Peptide presentation to CD4+ T cells
Signal 1 for T cell activation
Costimulatory signal (signal 2) for T cell activation
Costimulatory signal (signal 2) for T cell activation
Cell-cell adhesion
Costimulatory signal, specifically for CD8+ T cells
Granule-independent method of inducing apoptosis by CTLs
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Count
Count

4T1
14.4
40

EMT6
24.4
59

MHC I FITC
22.3
97

28.5
107

Count

MHC II PE
4.47
9.9

21.6
252.1

Count

Count

B7-1 APC
17.1
42

B7-2 PE
8.4
44

20.5
64

12.5
12

Count

ICAM-1 FITC
203.1
1803.96

Fas PE-Cy7
Figure 7: In vitro assessment of surface molecules on 4T1 and EMT6 cells before and after
irradiation by flow cytometry. 4T1 (left column) and EMT6 (right column) cells were stained
with MHC I, MHC II, Fas, ICAM-1, B7-1, and B7-2 surface markers before irradiation (orange
and blue) or after irradiation (red and green). Cells were taken from culture and stained with
antibody for an hour at room temperature or irradiated at 100 Gy and cultured for 24 hours
before staining. Gray shading represents negative control of cells (light gray) and irradiated cells
(dark gray). Numbers represent the difference of median fluorescence intensities (ΔMFI)
between stained cells and the negative control (regular) or stained irradiated cells and the
negative control (bold). This experiment was repeated three times and a representative from each
group is shown.
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Secretion of Immunosuppressive Cytokines varies between Cell Lines
Another way that tumor cells may evade the immune system is by secreting products that
suppress the anti-tumor immune response. In order to evaluate the immunosuppressive effects
secreted by each cell line, GM-CSF, IL-6, IL-10, MCP-1, TGF-β and VEGF cytokine levels
were measured using CBA or ELISA.
High levels of GM-CSF promote expansion of myeloid derived suppressor cells
(MDSCs)54. EMT6 cells secrete no GM-CSF before irradiation and show little secretion after
irradiation (Figure 8A). There is no significant difference between before and after irradiation,
and therefore no significant difference between vaccination and challenge with EMT6 cells.
However, there is a significant difference before and after irradiation in 4T1 cells. An increase
in GM-CSF secretion is seen over time and this increase is even further amplified in irradiated
4T1 cells. There is also a difference in GM-CSF secretion between 4T1 and EMT6 cells during
both the vaccination and challenge with viable cells.
MCP-1 has chemotactic activity for monocytes and T lymphocytes and regulates the
infiltration of macrophages into the tumor environment 55. Like GM-CSF, EMT6 cells secrete
significantly more MCP-1 than 4T1 cells during both the vaccination and challenge with viable
cells (Figure 8C). Within each cell line, the irradiated cells secrete significantly more MCP-1
than viable cells.
One way that TGF-β exerts its immunosuppressive effects is by inhibiting proliferation
and effector functions of T cells. TGF-β influences the development of T regulatory cells
(Tregs), which inhibit the ability of APCs to stimulate T cells56. EMT6 cells were found to
secrete significantly higher amounts of TGF-β than 4T1 cells (Figure 8D). This suggests that
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EMT6 cells have a stronger inhibition of APCs than 4T1 cells. No significant differences were
seen between irradiated and non-irradiated forms of each cell line indicating that relatively the
same amount of TGF-β is secreted during the vaccination and challenge.
IL-6 and VEGF are other immunosuppressive cytokines that are responsible for the
expansion and buildup of immature myeloid cells by blocking differentiation that inhibits the
activity of CD4+ and CD8+ T cells 57. The concentration of IL-6 produced by 4T1 cells
increased slightly over time, while EMT6 mediated IL-6 production decreased over time (Figure
8B). Although EMT6 cells secrete a higher amount of IL-6, the difference was not significant.
No significant difference was seen between irradiated 4T1 or irradiated EMT6 cells as well.
There was a significant difference in IL-6 secretion before and after irradiation in each cell line.
This indicates that there is significantly more IL-6 secreted during vaccination than during a
challenge. VEGF production is significantly higher in EMT6 cells than 4T1 cells both before
and after irradiation (Figure 8E). Unlike other cytokines, irradiation caused the down regulation
of VEGF. This suggests that VEGF is secreted at much lower levels during vaccinations than a
challenge with viable tumor cells.
We found no evidence of IL-10 secretion by either cell line (data not shown). We found
it interesting that EMT6 cells secrete higher amounts of 4 of the 5 immunosuppressive cytokines
since EMT6 cells are immunogenic. It is clear that immunogenicity is not completely influenced
by cytokine secretion alone and that other factors, such as B7-1 expression, may be mainly
responsible for the anti-tumor immune response.
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Figure 8: Assessment of in vitro immunosuppressive cytokine secretion by 4T1 and EMT6 cells.
Supernatants were taken from culture 24, 48, 72, and 96 hours after incubation. Cytokines GMCSF (A), IL-6 (B) and MCP-1 (C) were measured using CBA and TGF-β (D) and VEGF (E)
were measured using ELISA. For each group, the four bars represent secretion after 24, 48, 72
and 96 hours, respectively. Experiment was repeated 3 times and data indicates mean  SEM.
Statistics were generated in GraphPad using a two way ANOVA with Tukey’s posttest.
Asterisks were used to denote the following significance levels: *p0.05; **p0.01; ***p0.001;
****p0.0001
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Hybrid Vaccine Inhibits Recognition of EMT6 Cells
An inhibitory signal during vaccination may be produced by 4T1 cells that prevents
protection and an anti-tumor immune response. To test this, mice were vaccinated with both
irradiated 4T1 and EMT6 cells and then challenged with EMT6 cells alone to determine whether
irradiated 4T1 cells impacted protection immunity against EMT6 cells. As shown in Figure 9,
protection was observed in only 40% of mice. This is half of the survival rate from vaccinating
with irradiated EMT6 cells alone. Immediately after challenge, 5/5 mice grew tumors, but two
of the mice later experienced tumor regression by day 15 and 25 after challenge (Figure 9). The
largest tumor volume of mice that experienced a tumor regression was 29.16 mm3 7 days after
viable tumor challenge. However, tumor size during this time was not an appropriate indicator
of whether the mouse would experience tumor regression because two control mice and three
vaccinated mice had tumors smaller than 30 mm3 7 days after challenge. Of the vaccinated mice
that experienced large tumor growth, there was no difference in tumor growth between the
control and vaccinated mice. This suggests that 4T1 cells produce some inhibitory signal that
prevented some mice from rejecting the EMT6 cells.
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Figure 9: Hybrid vaccine generates little protection. Mice (n=5) were vaccinated on days 10 and
20 prior to tumor challenge with 5x105 EMT6 and 1x106 4T1 irradiated cells. On day 0, mice
were challenged with 5x105 EMT6 viable tumor cells. Control mice (n=5) were only challenged
on day 0. Tumor volumes were measured every 3 to 4 days with calipers in two perpendicular
directions. (A) Survival of mice vaccinated with hybrid vaccine compared to controls. (B) Tumor
volume of mice vaccinated with hybrid vaccine following challenge.
IFN- Exposure to 4T1 cells up-regulates MHC and B7-1
Cell-mediated immunity to tumors may be augmented by enhancing MHC and
costimulation signals. By increasing MHC I and MHC II expression, tumor cells may be
recognized by CTLs and recruit help from helper T cells. Costimulatory signals from B7
molecules may then induce an effector T cell response. In an effort to up-regulate MHC and
costimulatory molecule expression, 4T1 cells were cultured with 1ng/ml of IFN-γ for 24 hours.
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After incubation, cells were stained with antibodies or irradiated and stained with antibodies 24
hours later. Flow cytometric analysis shows that IFN-γ treatment up-regulates surface expression
of MHC I, II and B7-1 (Figure 10). IFN-γ treatment affected MHC II expression the most with a
4.4-fold increase compared to normal cells, followed by B7-1 (2.6-fold increase) and MHC I
(1.5-fold increase). Irradiation of IFN-γ treated 4T1 cells caused further increase in surface
molecule expression, suggesting that IFN-γ treatment and irradiation work in a synergistic
manner. After IFN-γ and irradiation, MHC I and II expression on 4T1 cells (Figure 10) was
higher than expression seen on irradiated EMT6 cells (Figure 7). Although B7-1 expression on
4T1 cells was increased by IFN-γ and irradiation, the ΔMFI was still lower than the MFI of
before and after irradiation.
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Figure 10: IFN-γ up-regulates surface MHC II and B7-1 of 4T1 cells in vitro. Cells were
exposed to 1 ng/ml IFN- γ for 24 hours in vitro. Following incubation with IFN- γ, cells were
taken from culture and stained with antibody for an hour at room temperature (pink) or irradiated
with 100 Gy and cultured for 24 hours before staining (purple). Gray shading represents
negative control of cells (light gray) and irradiated cells (dark gray). Numbers represent the
difference of median fluorescence intensities (ΔMFI) between stained cells and the negative
control. This experiment was repeated three times and a representative from each group is
shown.
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Protection from Irradiated Cells is Dose Dependent
A minimum threshold of irradiated cells required to induce immune memory was
measured in the EMT6 cell line. Mice were vaccinated with 1x106, 5x105, 2.5x105, 1.25x105,
6.25x104 or 3.12x104 irradiated EMT6 cells on days 10 and 20 prior to viable EMT6 tumor
challenge. After the challenge, mice were tracked for tumor growth and tumors were measured
every 3 to 4 days. With this tumor model, the data suggests a minimum vaccine dose of 250,000
cells is required to induce immune memory. Mice that were vaccinated with lower than 250,000
cells experienced small tumor formation immediately after viable tumor cell challenge, but the
tumor later regressed as shown in Figure 11. This phenomenon occurred in 2, 2 and 3 mice for
doses 1.25x105, 6.25x104 and 3.12x104, respectively. Although these mice experienced tumor
regression, we did not find it positive that mice experienced any tumor formation. Vaccinating
with 250,000 irradiated EMT6 cells was the only vaccination dose that no tumor growth was
observed so this was determined to be the minimum threshold to completely inhibit tumor
formation.
For vaccination doses higher than 250,000 irradiated cells, 1/5 mice for each dose
experienced tumor growth and were sacrificed once the tumor reached 2000 mm3. The mouse
vaccinated with 1x106 irradiated cells showed a delayed tumor growth starting 42 days after
challenge, while the mouse vaccinated with 5x105 irradiated cells showed no delay and
experienced tumor growth similar to control mice. Larger sample sizes are needed before
conclusive statements can be drawn about effect of tumor cell dose.
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Figure 11: Limiting EMT6 dose study. Mice were vaccinated on days 10 and 20 prior to tumor
challenge with 5x105 (n=5), 2.5x105 (n=5), 1.25x105 (n=5), 6.25x104 (n=3), or 3.12x105 (n=3)
irradiated EMT6 cells. On day 0, mice were challenged with 5x10 5 EMT6 viable tumor cells.
Tumors were measured every 3 or 4 days in two perpendicular directions.
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Discussion
Autologous cells as a form of breast cancer immunotherapy have numerous advantages
over current adjuvant therapies including patient specificity, minimal toxicity, and a potential of
maintaining long term immunity. Since tumor resection is indicated for the majority of breast
cancer patients, a source of tumor antigen is readily available for vaccination in the adjuvant
setting. A vital component of inducing protective immunity from cancer using cellular vaccines
is first inactivating tumor cells. Two common methods of inactivating cells are irradiation and
freeze/thaw. We found a distinct difference in the ability of irradiated and freeze/thawed cells to
establish immune memory. In an immunogenic cell line, prophylactic vaccination with
irradiated cells elicited protective immunity in 80% of mice, compared to 0% protection using
freeze/thawed cells. This is consistent with other reports in various mouse models 50 51. The
difference in protective immunity between each antigen form indicates a preference in the way
antigen is presented to the immune system. When administering cellular vaccines, inactivating
cells with irradiation will elicit stronger responses than freeze/thawed cells.
Although we did not analyze any further why irradiated cells provided better protection,
others have reported the in vivo effects and mechanistic results of vaccinating with both forms of
antigen. The in vivo effects of each vaccine, as reported by Scheffer et al., show that
freeze/thawed cells failed to induce a potent immune response that may be due to the infiltration
of various cells. Irradiated cells were able to bring strong infiltration of CD4+, CD8+, and
dendritic cells (DCs) at the injection site while freeze/thawed cells had no presence of these cells
10 days past injection and instead resulted in a strong macrophage infiltration 50. Furthermore, a
detailed in vivo mechanistic study with irradiated and freeze/thawed cells reports that both forms
of antigen are taken up by APCs and result in the cross-priming of naïve T cells. However while
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CD8+ T cells primed by irradiated cells expand and express full effector function, CD8+ T cells
primed by freeze/thawed cells do not accumulate and a smaller proportion become functional 58.
The accumulation of different cells, particularly the lack of CD8+ accumulation by
freeze/thawed cells, may be responsible for the differences in immune protection.
While vaccination with irradiated cells from an immunogenic cell line (EMT6) is able to
elicit protection, no protection was observed when vaccinating with a non-immunogenic cell line
(4T1). There must be a difference between 4T1 and EMT6 cells that prevents 4T1 cells from
inducing an anti-tumor immune response. Some surface markers, such as those used to classify
breast cancer subtype, may have an indirect influence on the anti-tumor immune response by
indicating aggressiveness of the cancer and potential of breast cancer recurrence. Presence of
hormone receptors and/or HER2 influences the prognosis and treatment options available to
breast cancer patients. Both 4T1 and EMT6 cells lack the ER, PR, and HER2 and therefore are
classified as TNBC. This subtype is known to have aggressive characteristics such as early
relapse and decreased survival. However, there is a lack of therapeutic treatments for TNBC due
to the absence of these receptors which may influence the survival trend 59. Since both the
immunogenic and non-immunogenic cell lines are triple negative for the ER, PR, and HER2, we
can assume that while these markers may influence the aggressiveness of cancer, they do not
determine immunogenicity. Protective immunity elicited by vaccinating with EMT6 cells
demonstrates the presence of immunogenic antigens other than HER2. Approximately only 40%
of women have HER2 positive breast cancer (Luminal B and HER2+ subtypes) and will benefit
from HER2 targeted therapy. Autologous cells may serve as a promising treatment option for all
breast cancer patients, but notably women with TNBC, due to presence and immunogenicity of
unknown antigens, as evident by EMT6 cells.
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Surface marker expression and cytokine secretion by each cell line may directly influence
the anti-tumor immune response by evading recognition by T cells or inhibiting their activation.
Tumors may down regulate MHC I to evade recognition, and therefore apoptosis, by CTLs.
Tumors may also lack MHC II expression, which is needed to activate helper T cells and aid in
differentiation of CTLs52. Both the 4T1 and EMT6 cell lines express MHC I and II at low levels
and should be able to carry out these processes.
Costimulators are also needed to initiate T cell responses52. The best characterized
costimulatory molecules are B7-1 and B7-2 which bind to CD28 on a naïve T cell. Expression
of B7 is imperative because through multiple mechanisms, engagement of CD28 induces
differentiation of effector and memory cells 52. The most notable difference observed between
the surfaces of each cell line was the up-regulation of B7-1 in EMT6 cells after irradiation, while
irradiated 4T1 cells only saw a small up-regulation. This suggests that EMT6 cells may provide
a strong costimulatory signal through the B7-1 molecule and enhance T cell activation, while
4T1 cells are not.
IFN-γ is a known regulator of B7 molecule expression on APCs. In the 4T1 tumor
microenvironment, there is not enough IFN-γ in the tumor microenvironment to up-regulate
genes until 15 days after implantation60, after tumor cells have already metastasized. Gene
transfer of MHC II or B7-1 reduces metastases and tumorigenicity of 4T1 cells 61. Treatment of
4T1 cells with only 1ng/ml IFN-γ for 24 hours at least doubles MHC II and B7-1 expression and
a further increase is seen after irradiation. However, increase in B7-1 expression still is not
comparable to B7-1 expression on irradiated EMT6 cells. It is not clear how much B7-1
expression is needed to benefit the anti-tumor immune response or if any protection would be
observed in mice vaccinated with IFN-γ treated irradiated 4T1 cells.
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Once CTLs are activated, they may perform granule-independent killing, through
Fas/FasL interaction, or granule-dependent killing, through ICAM-1/LFA-1 interaction. Once
FasL on the surface of the CTL attaches to the death receptor Fas on the target cell, apoptosis is
initiated in the Fas expressing target. Both 4T1 and EMT6 express Fas and show an upregulation following irradiation suggesting that CTLs, which express FasL, should be able to
eliminate both tumor cell lines through a granule-independent mechanism as long as CTLs are
present. ICAM-1 is a cellular adhesion molecule and functions as a costimulator, specifically for
CD8+ cells. ICAM-1 is hardly expressed on 4T1 or EMT6 cells, but irradiation results in an
increase in ICAM-1 expression on 4T1 cells. Since both cell lines express little ICAM-1 and
high levels of Fas, we assume that each cell line is likely killed in a granule-independent manner.
Immunosuppressive cytokine secretion is another way that tumor cells may escape
immune defenses. Cytokines can influence the immune system to promote immunosuppression
and tumor growth by inhibiting T cell activation and regulating expansion, recruitment and
differentiation of various cells. MCP-1 regulates the infiltration of macrophages in the tumor
environment and also influences T cell differentiation through IL-4, which inhibits a Th1 CD4+
T cell response critical for the elimination of cancer 55. TGF-β also inhibits a Th1 response,
along with inhibiting NKs, CTLs, and macrophages that results in prevention of anti-tumor
immunity 56, 62. However, TGF-β has both tumor promoting and tumor suppressive effects,
which is dependent upon the stage of cellular transformation. As a tumor suppressor, TGF-β
increases apoptosis of cancer cells and inhibits expression of growth factors, including GM-CSF
56, 63

. IL-6 and VEGF are other immunosuppressive cytokines that are responsible for the

expansion and buildup of immature myeloid cells by blocking differentiation that inhibits the
activity of CD4+ and CD8+ T cells 57. VEGF prevents DC precursors from developing into
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antigen-presenting DCs and is associated with the accumulation of tumor associated
macrophages64. We show that EMT6 cells produce higher amounts of each immunosuppressive
cytokine tested than 4T1 cells, except for GM-CSF. We found it interesting that the
immunogenic cell line actually secretes more immunosuppressive cytokines than the nonimmunogenic cell line. It is not clear if there is a dominant immunosuppressive cytokine or if
certain cytokines synergize to create a more suppressed immune system. Since GM-CSF
production is the major difference between each cell line, future studies will focus on the knockout or knock-in of GM-CSF in 4T1 and EMT6 cells, respectively.
GM-CSF production is a double-edged sword. In the B16 melanoma mouse model, GMCSF was shown to be the most potent stimulator of anti-tumor immunity out of IL-2, IL-4, IL-5,
IL-6, IFN-g, IL-1RA, ICAM, CD2, and human TNF-a 45. Vaccines in conjunction with GMCSF as an adjuvant result in enhanced tumor antigen presentation by dendritic cells and
macrophages 65. However, GM-CSF has also been reported to promote the expansion of MDSCs
in the mouse, characterized by the CD11b and Gr1 markers 54. Upon investigation, GM-CSF
gives either a stimulating or inhibitory signal to the immune system depending on the level of
cytokine secretion. In a model by Serafini, the upper threshold of stimulating the immune system
through GM-CSF secretion was 206 pg/ml 54. We show that not only do 4T1 cells produce a
significantly greater amount of GM-CSF than EMT6 cells both before and after irradiation, but
that the secretion level is well above the 206 pg/ml upper threshold. Therefore, 4T1 cells may be
recruiting a large number of MDSCs resulting in immunosuppression rather than immune
stimulation.
We confirmed production of an inhibitory signal by 4T1 cells with creation of a hybrid
vaccine that consisted of both irradiated 4T1 and EMT6 cells. After a challenge with viable
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EMT6 cells, 60% of mice developed a tumor. Importantly, immediately after the challenge with
EMT6 cells all mice grew a tumor, but two mice later had tumor regression. Half of the
protection is observed when vaccinating with both cell lines rather than vaccinating with EMT6
cells alone (40% vs. 80%). Therefore, an inhibitory signal must be produced by 4T1 cells during
vaccination to prevent the recognition of EMT6 cells. It is not clear what the
immunosuppressive signal is that prevents recognition of EMT6 cells. We predict that over
production of GM-CSF takes some role in the immunosuppressive signal since this is the only
immunosuppressive cytokine that we tested that EMT6 cells did not produce. We are not sure
whether GM-CSF is acting alone or synergizing with the other immunosuppressive cytokines or
surface molecules to prevent immune protection from 4T1 cells and EMT6 cells in the hybrid
vaccine.
Secretion of large amounts of immunosuppressive cytokines leads to splenomegaly,
which is observed due to massive granulocytic infiltrates 66. These infiltrates, such as MDSCs,
are an obstacle to active immunotherapy because they block the activation of tumor reactive T
cells and induce accumulation of Tregs 67, another splenocyte population associated tumorassociated immune suppression 46. Almost 50% of cells in the spleen of a 4T1 tumor bearing
mouse are CD11b+Gr1+ 66, whereas the same cell population in the spleen of an EMT6 tumor
bearing mouse is 20%57. The lower concentrations of MDSCs in the spleen of EMT6 mice may
partly be attributed to the lack of GM-CSF secretion.
Additionally, there is a minimum limit in which irradiated cells are able to confer
immunity and in the EMT6 model the limit is 250,000. In order to administer a successful
therapeutic vaccine at least 250,000 cells must be obtained following tumor resection in the
EMT6 model. Using a triple enzyme digestion method (See Appendix), we are able to obtain
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approximately 2x106 tumor cells per 0.5 g of tumor. Therefore, we are able to obtain more than
enough cells needed for a therapeutic vaccine. Therapeutic studies are critical for future studies
for a more accurate representation of the clinical setting.
Our studies confirm that irradiated cells serve as a better vaccination than freeze/thawed
cells and provide a possible explanation for the lack of protection from 4T1 cells when
administered as a vaccine. Based on the differences in the immunogenic profile of each cell line,
a direction for future studies involves the manipulation of 4T1 cells through changes in surface
molecules and cytokine secretion in hopes of developing a more immunogenic tumor.

Chapter 4: Future Perspective
Introduction
A majority of breast cancer patients will undergo surgery following diagnosis of breast
cancer. Following surgery, majority of patients are given adjuvant therapy in an attempt to
eliminate tumor cells that may have disseminated from the primary tumor. Adjuvant therapy,
such as chemotherapy, radiation therapy, hormonal or targeted therapy, have toxic side effects
and benefit only a subset of patients. Still, 1 out of 5 patients go on to have a recurrence after 10
years. Since the majority of breast cancer deaths are due to the recurrence and progression of
non-metastatic disease, an intervention is needed that promotes the immune system to eradicate
lingering tumor cells after surgery. The use of autologous whole tumor cells as adjuvant therapy
has shown pre-clinical and clinical success for promoting an anti-tumor immune response.
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Future Pre-Clinical Studies
Pre-clinically, we have demonstrated the effectiveness of an autologous whole cell breast
cancer vaccine using a murine model. In the EMT6 cell line, 80% of mice vaccinated with
autologous cell later reject a challenge with live cells. However, vaccinations were only
successful in an immunogenic cell line. Mice vaccinated with irradiated 4T1 cells, showed no
protection or delay in tumor growth. Using the differences observed between the immunogenic
profiles, each cell line may be manipulated to change expression of surface molecules or
secretion of cytokines in an effort to understand their role in immunogenicity. The advancement
of immunotherapy for 4T1 cells is dependent on the understanding of various characteristics of
the immunogenic profile and the influence they have on immunogenicity.
By altering the immunosuppressive cytokine profile and therefore the various cell
infiltrates in the spleen and tumor, we may be able to change the “immunogenic profile” of a 4T1
tumor into an immunogenic tumor that is capable of immune protection. We believe that down
regulation of GM-CSF secretion shows the most potential in eradicating the immunosuppressive
signal secreted by 4T1 cells. EMT6 cells secrete no GM-CSF and other studies have shown that
GM-CSF levels above 206 pg/ml induce a suppressive immune signal, so we believe that
significantly lowering or knocking out GM-CSF in 4T1 cells will promote the anti-tumor
immune response. Significant, but not total, knockout of GM-CSF in 4T1 cells results in
reduction of CD11b+Gr1+ splenocytes 68. Since MDSCs are a hindrance to immunotherapy, by
reducing GM-CSF and therefore MDSCs accumulation, the immune system may be able to elicit
some tumor protection. Another study may include a gene encoding GM-CSF to be inserted in
EMT6 cells to experiment whether GM-CSF secretion by EMT6 cells would hinder protection.
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Other immunosuppressive cytokines may also be knocked out in 4T1 cells. Treatment of
a 4T1 tumor with an anti-TGF-β antibody also showed a decrease of CD11b+Gr1+ splenocytes.
When mice were treated therapeutically with an anti-TGF-β antibody, approximately 30% of
mice survived56. Future studies may explore a knockout of TGF-β in a prophylactic vaccine of
4T1 cells alone or in combination with GM-CSF knockout.
In addition to cytokine secretion, surface molecules may influence the anti-tumor
immune response. Gene transfer of MHC II and B7-1 reduces the metastatic and tumorigenic
capability of 4T1 cells. Vaccinating with 4T1 cells that have been transduced with MHC II
and/or B7-1 may increase initiation of T cell responses supplying a stronger immune response
following challenge. We show that IFN- up-regulates MHC I, II and B7-1 in vitro and the
increase in expression of these surface markers may be enough to elicit some tumor protection.
Additionally, vaccinating with a B7-1 knockout in the EMT6 cell line may also indicate the
influence of B7-1 in immunogenicity of tumor cells.
In addition to the future studies mentioned above, therapeutic vaccinations may be
implemented to more accurately represent the current clinical setting. After surgery, tumor cells
may be left behind because either the whole tumor may not have been removed or tumor cells
have already travelled to other local or distant parts of the body. Prophylactic vaccinations do
not take into account existing tumor cells, and possible immunosuppression, while therapeutic
vaccinations do. Since the primary treatment of breast cancer is surgery, it is important to study
vaccinations following tumor resection.
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Implementation in the Clinic
Clinically, less success has been observed compared to pre-clinical models. Three key
questions need to be addressed regarding development autologous tumor cell vaccines to
improve clinical results. First, immunogenicity of the cells will need to be improved through
better delivery and inactivation of the cells. It has been shown pre-clinically that GM-CSF is a
strong immune system stimulator. However, GM-CSF and IL-2 works synergistically to provide
an immune response stronger than each adjuvant individually69. Different adjuvant formulations
should be investigated to determine what best stimulates a patient’s immune system. For
example, 67% of mice treated intratumorally with chitosan/IL-12 prior to tumor resection
became tumor free. All mice were later protected following a challenge with viable 4T1 cells,
suggesting that this treatment made 4T1 cells immunogenic.
Second, a signature of what makes a tumor immunogenic would be helpful in identifying
patients that will benefit from vaccination. Tumor antigen expression, number of T cell
infiltrates, immunosuppression all could have an impact on how well a patient responds to
vaccination. For example, establishment of an immune score based on cytotoxic and memory T
cells in colorectal cancer has shown to improve prediction of tumor recurrence70, 71. An immune
score should be applicable to most human tumors72, including breast cancer. T-cell infiltration in
breast cancer has been associated with favorable prognoses73, 74, although extent of recurrencefree and overall survival with high T-cell infiltration is not known. By identifying patients that
respond to vaccination and characterizing their tumor and tumor microenvironment, we may be
able to determine patients with a high-risk of recurrence and patients that may benefit from
immunotherapy. Additionally, by identifying what makes a tumor immunogenic we may be able
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to manipulate tumor cells for patients who originally would not respond as well to
immunotherapy in an effort to increase immune system activation.
Third, a standardization of preparing vaccines is important for consistent results. Once a
tumor has been removed from a patient, standard protocols are needed for dissociating the tumor.
Common methods include enzymes such as DNAse and collagenase. Then cells must be either
cryopreserved or cultured for the duration of immunotherapy. Finally, cells must be prepared to
give back to the patient. Often cells are either irradiated or treated with Mitomycin C. The
numerous methods of preparing autologous tumor cells must be optimized so that they give the
greatest immune response and give reliable results. After preparation, the location of
administration and duration of the immunotherapy should be standardized as well. By solving
these three key challenges, autologous whole tumor cell vaccines may produce clinically
significant results that build on the success of improved over-all and recurrence free-survival that
has already been achieved.
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Appendix
Freeze/Thaw cells with -80°C Ethanol

In an effort to vaccinate mice with cell lysates, cells were subjected to 5 freeze/thaw cycles while
suspended in DPBS using a 37°C water bath and -80°C 70% ethanol and distilled water mixture.
Mice were injected with 1x106 freeze/thawed 4T1 (n=4) or EMT6 (n=4) cells. However, this
model did not serve as an appropriate method for freeze/thawing cells. Shortly after vaccination,
mice began to grow tumors suggesting that a significant number of cells survived the freeze/thaw
cycles. 100% of mice injected with 4T1 cells grew tumors, while 75% of mice injected with
EMT6 cells grew tumors.
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Triple Enzyme Mouse Tumor Digestion
Preparation
10X Triple Enzyme Stock Solution:
Collagenase 1 g f.c. [10 mg/ml]
Hyaluronidase 100 mg f.c. [1 mg/ml]
DNase 20,000 Units f.c. [200 mg/ml]
HBSS 100 ml
Sterile filter (0.22 m) and store 5 ml aliquots at –20°C.
Thaw at RT (NOT 37°C) before use.
Procedure
1. Remove tumor and place into a 60 or 100 mm petri dish and add 5-10 ml HBSS
2. Quickly mince tumor into fragments small enough to be pulled into a 5 ml pipette without
getting stuck.
3. Transfer to 50 ml conical tube.
4. Rinse petri dish with up to 40 ml HBSS and transfer to tube. Total volume in tube should be
45 ml (if not, bring up to volume with HBSS).
5. Add 5 ml 10X Triple Enzyme Mix to the tube and place on rotisserie for 1 hr.
6. Pass cells through 70 μm nylon mesh filter unit into a second 50 ml conical tube.
7. Pellet cells at 1200 rpm for 8 min.
8. Aspirate supernatant and resuspend cells in 15ml cell medium.
9. Carefully layer the cell suspension on top of 15ml Histopaque.
10. Centrifuge the sample at 400xg for 30 minutes with acceleration set at “1” and deceleration
set at “0”.
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11. At the end of the spin, an opaque layer of cells should be observed at the interphase of the
histopaque and cell medium layers. Transfer these live cells carefully to a 15ml tube. Bring total
volume to 15ml with cell medium if needed.
12. Centrifuge 15ml tube at 2000rpm for 10 minutes.
13. Aspirate supernatant and resuspend cells in 1ml medium.
14. Count cells.
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